Trial Profile
SK-1403 Long-term Treatment Study - Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Upacicalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational
- Sponsors Sanwa Kagaku Kenkyusho
- 01 Mar 2022 According to a Pathalys Pharma media release, Upacicalcet was granted Marketing Authorization in Japan in 2021, under the brand name UPASITA, based on a phase 3, 24-week double-blind, placebo-controlled dose-titration study and a second phase 3, 52-week open-label, dose-titration study.
- 06 Mar 2020 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Status changed from recruiting to active, no longer recruiting.